Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Long-Term Deferred Tax (2016 - 2019)

Historic Long-Term Deferred Tax for Niagen Bioscience (NAGE) over the last 5 years, with Q4 2019 value amounting to $30.5 million.

  • Niagen Bioscience's Long-Term Deferred Tax rose 3834.34% to $30.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $30.5 million, marking a year-over-year increase of 3834.34%. This contributed to the annual value of $30.5 million for FY2019, which is 3834.34% up from last year.
  • According to the latest figures from Q4 2019, Niagen Bioscience's Long-Term Deferred Tax is $30.5 million, which was up 3834.34% from $22.1 million recorded in Q4 2018.
  • Niagen Bioscience's Long-Term Deferred Tax's 5-year high stood at $30.5 million during Q4 2019, with a 5-year trough of $13.0 million in Q4 2017.
  • Moreover, its 4-year median value for Long-Term Deferred Tax was $15.9 million (2016), whereas its average is $19.4 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first crashed by 1808.65% in 2017, then skyrocketed by 6913.7% in 2018.
  • Quarter analysis of 4 years shows Niagen Bioscience's Long-Term Deferred Tax stood at $15.9 million in 2016, then dropped by 18.09% to $13.0 million in 2017, then soared by 69.14% to $22.1 million in 2018, then soared by 38.34% to $30.5 million in 2019.
  • Its Long-Term Deferred Tax stands at $30.5 million for Q4 2019, versus $22.1 million for Q4 2018 and $13.0 million for Q4 2017.